2023-07-18 09:46:37
The listing of the action of the biotech argenx, specializing in the treatment of autoimmune diseases and cancer, was suspended on Tuesday on the Brussels Stock Exchange, announced the FSMA, the stock market policeman.
The suspension took effect at 9 a.m. Tuesday and came pending the publication of a press release.
The announcement of encouraging results around a new drug made the argenx share jump by more than 31% on Monday on the Brussels Stock Exchange.
After the success of a clinical trial which boosted its action on Monday (+31%), argenx launched a global offer on Monday evening to raise 750 million dollars.
1689680644
#company #raise #million #dollars #action #suspended #Brussels #Stock #Exchange
